uploads/2019/04/toothpaste-3662843_1280.jpg

What’s on the Horizon for Colgate-Palmolive Stock?

By

Updated

Colgate-Palmolive

Recently, Colgate-Palmolive’s (CL) quarterly results were impressive. The company beat analysts’ estimates following continued momentum in organic sales. Given the consistent improvement in the underlying business, multiple analysts raised their target price on the stock. J.P. Morgan upgraded Colgate-Palmolive stock to “neutral” from “underweight” and raised the target price to $70 per share from $62.

Analysts made the following upgrades to the target price:

Article continues below advertisement
  • Wells Fargo raised the target price from $62 to $65.
  • Jefferies increased the target price to $73 from $61.
  • Morgan Stanley has a target price of $68—up from $62.
  • J.P. Morgan raised the target price to $70 from $62.
  • Credit Suisse increased the target price to $60 from $55.
  • SunTrust Robinson raised the target price from $65 to $70.
  • Macquarie increased the target price by $7 to $72.

Rating and target price summary

Most of the analysts maintained a neutral stance on Colgate-Palmolive stock. Persistent challenges will likely limit the upside. Among the 23 analysts covering Colgate-Palmolive stock, 14 recommended a “hold,” six recommended a “buy,” and three recommended a “sell.” Other major consumer packaged goods companies had consistent organic sales growth. However, sales and margin headwinds are keeping analysts on the sidelines.

Analysts have a neutral outlook on Procter & Gamble (PG), Church & Dwight (CHD), Kimberly-Clark (KMB), and Clorox (CLX) stock.

Analysts have a consensus target price of $69.64 on Colgate-Palmolive stock, which suggests a downside of 2.4% based on its closing price of $71.38 on April 29.

Advertisement

More From Market Realist